89 completed, 43 unknown, 16 recruiting, 15 terminated. 173 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 173 | Completed 89, Unknown 43, Recruiting 16, Terminated 15, Active not recruiting 4, Not yet recruiting 3, Withdrawn 2, Enrolling by invitation 1 |
Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy Cosibelimab, Prednisone, Sirolimus - Cutaneous Squamous Cell Carcinoma, Skin Cancer | Phase 4 | Recruiting | Dana-Farber Cancer Institute | 80 | 2026-04-23 | 2026-08-11 |
| A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Pirtobrutinib, Idelalisib - Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic | Phase 4 | Recruiting | Eli Lilly and Company | 150 | 2026-03-09 | 2026-11-04 |
| Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates - AML (Acute Myeloid Leukemia), Glioma | Phase 4 | Recruiting | Rigel Pharmaceuticals | 16 | 2026-02-23 | 2026-08-11 |
| Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase Levofloxacin, Placebo - Neutropenic Fever, Acute Lymphoblastic Leukemia | Phase 4 | Terminated | Gadjah Mada University | 49 | 2026-01-01 | 2026-10-01 |
| Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 4 | Recruiting | AbbVie | 100 | 2025-07-24 | 2026-09-11 |
| Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies Ceftazidime, Ciprofloxacin - Neutropenic Fever, Acute Lymphoblastic Leukemia | Phase 4 | Recruiting | Gadjah Mada University | 120 | 2025-06-01 | 2025-08-22 |
| A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma Pirtobrutinib - Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | Phase 4 | Recruiting | Eli Lilly and Company | 279 | 2025-05-20 | 2026-03-02 |
| A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib Pirtobrutinib - Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | Phase 4 | Recruiting | Eli Lilly and Company | 787 | 2025-05-20 | 2026-03-02 |
| Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure Acalabrutinib, Investigator's choice of treatment - Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment | Phase 4 | Recruiting | AstraZeneca | 60 | 2025-02-04 | 2026-09-24 |
| CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML Cladribine, Cytarabine, G-CSF - Relapsed/Refractory AML | Phase 4 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 172 | 2025-02-01 | 2025-01-08 |
| Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma Dexamethasone, Vincristine, Daunorubicin - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 4 | Recruiting | St. Jude Children's Research Hospital | 850 | 2024-12-26 | 2026-07-14 |
| Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation Asciminib - Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase | Phase 4 | Completed | Novartis Pharmaceuticals | 85 | 2024-11-28 | 2026-06-08 |
| Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality Oral Azacitidine - Acute Myeloid Leukemia | Phase 4 | Recruiting | Virginia Commonwealth University | 12 | 2024-11-07 | 2026-11-05 |
| Antimicrobial Revision in Persistent Febrile Neutropenia Meropenem, Micafungin - Febrile Neutropenia | Phase 4 | Withdrawn | Wake Forest University Health Sciences | 2024-08-01 | 2024-09-19 | |
| RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR Venetoclax, Allogeneic transplant - Acute Myeloid Leukemia | Phase 4 | Recruiting | He Huang | 118 | 2024-07-17 | 2024-08-26 |
| Exploring the Minimum Effective Concentration and Volume of Ropivacaine for Sacral Plexus Anesthesia Low-dose ropivacaine, Medium-dose of ropivacaine, High-dose ropivacaine - Pediatric ALL | Phase 4 | Enrolling by invitation | Yilin Zhao | 180 | 2024-05-10 | 2024-12-02 |
| Belimumab After Rituximab in Resistant Primary Juvenile SS Rituximab, Belimumab - Sjogren's Syndrome, Pediatric ALL | Phase 4 | Recruiting | Peking Union Medical College Hospital | 15 | 2024-03-09 | 2024-05-16 |
| Stopping Antibiotics After 3 Days for the Treatment of High-risk FEbrile Neutropenia Comparison short vs extended EBAT treatment group - Neutropenia, Febrile | Phase 4 | Completed | Universitaire Ziekenhuizen KU Leuven | 450 | 2024-02-26 | 2026-10-23 |
| The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery Bridion 200 MG in 2 ML Injection, Pyridostigmine Bromide 5 MG/ML - Emergence Delirium, Strabismus | Phase 4 | Completed | Konkuk University Medical Center | 76 | 2023-12-01 | 2026-07-15 |
| Hepatoprotective Measures for Children at High Risk of NAFLD Ursodeoxycholic Acid 250 Mg Oral Capsule, Omega -3 fatty acids, Physical exercise - Non Alcoholic Fatty Liver Diseases (NAFLD), Obesity and Overweight | Phase 4 | Active not recruiting | Ain Shams University | 200 | 2023-11-19 | 2025-04-09 |
Showing 20 of 173. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (60) · Leukemia, Myeloid, Acute (41) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (29) · Leukemia, Lymphocytic, Chronic, B-Cell (16) · Lymphoma (10) · Myelodysplastic Syndromes (9) · Leukemia, Myeloid, Chronic-Phase (8) · Lymphoma, Non-Hodgkin (8) · Recurrence (8) · Febrile Neutropenia (7) · Leukemia, Promyelocytic, Acute (7) · Neoplasm, Residual (6) · Neoplasms (5) · Graft vs Host Disease (4)
Hemic and Lymphatic Diseases (173) · Neoplasms by Histologic Type (173) · Hematologic Diseases (171) · Neoplasms (168) · Immune System Diseases (90) · Lymphoproliferative Disorders (86) · Immunoproliferative Disorders (85) · Lymphatic Diseases (85) · Leukemia, Myeloid (83) · Leukemia, Lymphoid (79) · Pathological Conditions, Signs and Symptoms (72) · Pathologic Processes (68) · Disease Attributes (57) · Chronic Disease (51)
Cytarabine (34) · Cyclophosphamide (21) · Vincristine (20) · Methotrexate (18) · Dexamethasone (17) · Idarubicin (16) · Mercaptopurine (16) · Daunorubicin (15) · nilotinib (15) · Imatinib Mesylate (13) · Asparaginase (12) · Granulocyte Colony-Stimulating Factor (12) · fludarabine (12) · Rituximab (11) · Doxorubicin (10)
Novartis Pharmaceuticals (17) · PETHEMA Foundation (16) · Goethe University (5) · Pfizer (4) · Technische Universität Dresden (4) · Ain Shams University (3) · Eli Lilly and Company (3) · Hoffmann-La Roche (3) · Johann Wolfgang Goethe University Hospital (3) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (3) · Shenzhen Second People's Hospital (3) · AbbVie (2) · AstraZeneca (2) · Chinese Academy of Medical Sciences (2) · Gadjah Mada University (2)
China (37) · United States (36) · Spain (28) · Germany (25) · France (18) · Italy (15) · United Kingdom (13) · Poland (12) · South Korea (11) · Canada (10) · Sweden (9) · Belgium (8) · Austria (7) · Hungary (7) · India (7)
Dieter Hoelzer, MD,PhD (4) · Sanz Miguel Angel, Dr (4) · Gerhard Ehninger, MD (3) · Xiaofan Zhu, MD (3) · Adolfo Martinez Tovar, PhD (2) · Bastida Pilar, Dr (2) · Dieter Hoelzer, MD, PhD (2) · Jun Ma (2)
PMID 36064577, PMID 19144982, PMID 22442346, PMID 22493293, PMID 23024237, PMID 24923295, PMID 27561722, PMID 28751559, PMID 28945881, PMID 10231138, PMID 10583235, PMID 11863096, PMID 12627513, PMID 14585365, PMID 14752084, PMID 15014526, PMID 15158091, PMID 15257960, PMID 15770833, PMID 16110027, PMID 16197446, PMID 17223475, PMID 17410187, PMID 18056840, PMID 18398750, PMID 18626005, PMID 19167677, PMID 19564304, PMID 19720924, PMID 19822296, PMID 19951974, PMID 20220063, PMID 20393132, PMID 20442365, PMID 20542125, PMID 20625136, PMID 21148082, PMID 21266057, PMID 21670449, PMID 21775497, PMID 21828124, PMID 21940824, PMID 22197676, PMID 22198540, PMID 22241828, PMID 22290953, PMID 22318524, PMID 22512017, PMID 22677206, PMID 22871557
2009 (3), 2005 (1), 2014 (1), 2015 (1), 2016 (1), 2018 (1), 2019 (1), 2023 (1), P01CA128115 (1), P30CA021765 (1), R01CA078957 (1), R01CA091912 (1), U01CA081445 (1)